Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Anika Therapeutics (ANIK) over the last 14 years, with Q2 2025 value amounting to $311335.0.

  • Anika Therapeutics' Gains from Sales and Divestitures rose 427.43% to $311335.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $311335.0, marking a year-over-year increase of 427.43%. This contributed to the annual value of $311441.0 for FY2024, which is 1889.83% up from last year.
  • Anika Therapeutics' Gains from Sales and Divestitures amounted to $311335.0 in Q2 2025, which was up 427.43% from $250172.0 recorded in Q1 2025.
  • Anika Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $311441.0 during Q4 2024, with a 5-year trough of $87953.0 in Q1 2022.
  • In the last 5 years, Anika Therapeutics' Gains from Sales and Divestitures had a median value of $248542.5 in 2023 and averaged $213685.8.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 215032.5% in 2021, then increased by 18.26% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Gains from Sales and Divestitures stood at $91680.0 in 2021, then surged by 79.07% to $164167.0 in 2022, then skyrocketed by 59.56% to $261939.0 in 2023, then increased by 18.9% to $311441.0 in 2024, then fell by 0.03% to $311335.0 in 2025.
  • Its last three reported values are $311335.0 in Q2 2025, $250172.0 for Q1 2025, and $311441.0 during Q4 2024.